This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Trifirò G, Sultana J, Bate A. From big data to smart data for pharmacovigilance: the role of healthcare databases and other emerging sources. Drug Saf. 2018;41(2):143–9. https://doi.org/10.1007/s40264-017-0592-4.
Raghupathi W, Raghupathi V. Big data analytics in healthcare: promise and potential. Health Inf Sci Syst. 2014;2:3. https://doi.org/10.1186/2047-2501-2-3.
US Department of Health and Human Services, US Food and Drug Administration, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research. Use of real-world evidence to support regulatory decision-making for medical devices. Guidance for industry and Food and Drug Administration staff. 2017. http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm513027.pdf. Accessed 8 Jul 2018.
Pacurariu AC, Straus SM, Trifirò G, Schuemie MJ, Gini R, Herings R, et al. Useful interplay between spontaneous ADR reports and electronic healthcare records in signal detection. Drug Saf. 2015;38(12):1201–10. https://doi.org/10.1007/s40264-015-0341-5.
Patadia VK, Schuemie MJ, Coloma PM, Herings R, van der Lei J, Sturkenboom M, et al. Can electronic health records databases complement spontaneous reporting system databases? A historical-reconstruction of the association of rofecoxib and acute myocardial infarction. Front Pharmacol. 2018;9:594. https://doi.org/10.3389/fphar.2018.00594.
Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017. https://doi.org/10.1126/scitranslmed.aag1166.
Lorberbaum T, Sampson KJ, Woosley RL, Kass RS, Tatonetti NP. An integrative data science pipeline to identify novel drug interactions that prolong the QT interval. Drug Saf. 2016;39(5):433–41. https://doi.org/10.1007/s40264-016-0393-1.
Xiao C, Li Y, Baytas IM, Zhou J, Wang F. An MCEM framework for drug safety signal detection and combination from heterogeneous real world evidence. Sci Rep. 2018;8:1806. https://doi.org/10.1038/s41598-018-19979-7.
Comfort S, Perera S, Hudson Z, Dorrell D, Meireis S, Nagarajan M, et al. Sorting through the safety data haystack: using machine learning to identify individual case safety reports in social-digital media. Drug Saf. 2018;41(6):579–90. https://doi.org/10.1007/s40264-018-0641-7.
Busby J, Mills K, Zhang S-D, Liberante FG, Cardwell CR. Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study. Breast Cancer Res. 2018;20:4. https://doi.org/10.1186/s13058-017-0928-0.
US Food and Drug Administration. FDA’s Sentinel initiative: background. 2017. http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149340.htm. Accessed 9 Jul 2018.
Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018;25:969–75. https://doi.org/10.1093/jamia/ocy032.
Becker BFH, Avillach P, Romio S, van Mulligen EM, Weibel D, Sturkenboom MCJM, et al. CodeMapper: semiautomatic coding of case definitions: a contribution from the ADVANCE project. Pharmacoepidemiol Drug Saf. 2017;26(8):998–1005. https://doi.org/10.1002/pds.4245.
McDonald SA, Nijsten D, Bollaerts K, Bauwens J, Praet N, van der Sande M, et al. Methodology for computing the burden of disease of adverse events following immunization. Pharmacoepidemiol Drug Saf. 2018;27(7):724–30. https://doi.org/10.1002/pds.4419.
European Medicines Agency. Identifying opportunities for “big data” in medicines development and regulatory science: report from a workshop held by EMA on 14-15 November 2016. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/02/WC500221938.pdf. Accessed 8 Jul 2018.
Schneeweiss S, Eichler H-G, Garcia-Altes A, Chinn C, Eggimann A-V, Garner S, et al. Real world data in adaptive biomedical innovation: a framework for generating evidence fit for decision-making. Clin Pharmacol Ther. 2016;100(6):633–46. https://doi.org/10.1002/cpt.512.
Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open. 2018;8:e019759. https://doi.org/10.1136/bmjopen-2017-019759.
Gagne J, Han X, Hennessy S, Leonard C, Chrischilles E, Carnahan R, et al. Successful comparison of US Food and Drug Administration Sentinel analysis tools to traditional approaches in quantifying a known drug-adverse event association. Clin Pharmacol Ther. 2016;100(5):558–64. https://doi.org/10.1002/cpt.429.
Zhou X, Douglas IJ, Shen R, Bate A. Signal detection for recently approved products: adapting and evaluating self-controlled case series method using a US claims and UK electronic medical records database. Drug Saf. 2018;41(5):523–36. https://doi.org/10.1007/s40264-017-0626-y.
Caster O, Sandberg L, Bergvall T, Watson S, Norén GN. vigiRank for statistical signal detection in pharmacovigilance: first results from prospective real-world use. Pharmacoepidemiol Drug Saf. 2017;26:1006–10. https://doi.org/10.1002/pds.4247.
Wang SV, Schneeweiss S, Berger ML, Brown J, de Vries F, Douglas I, et al. Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies V1.0. Pharmacoepidemiol Drug Saf. 2017;26:1018–32. https://doi.org/10.1002/pds.4295.
The authors thank the speakers and attendees for the successful first conference on big data for pharmacovigilance.
No funding was received for the preparation of this meeting report.
Conflict of interest
Jae Min is a full-time PhD student at the University of Florida and has received an honorarium for writing the meeting report. Her travel was supported by the Center for European Studies and the Graduate Student Council at the University of Florida. Vicki Osborne, Elizabeth Lynn, and Saad Shakir are employees of the Drug Safety Research Unit, who sponsored this conference. Jae Min, Elizabeth Lynn, Vicki Osborne, and Saad Shakir have no conflicts of interest that are directly relevant to the contents of this meeting report.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Min, J., Osborne, V., Lynn, E. et al. First Conference on Big Data for Pharmacovigilance. Drug Saf 41, 1281–1284 (2018). https://doi.org/10.1007/s40264-018-0727-2